Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29440692 | 1.00 | KMT2A (0.40) | KMT2AMEN1F10LRRK2SCN2A | |
| SCHEMBL22734534 | 0.93 | KMT2A (0.42) | KMT2AMEN1F10TP53USP2 | |
| SCHEMBL22734607 | 0.90 | USP2 (0.39) | KMT2AMEN1F10TP53USP2 | |
| SCHEMBL22734631 | 0.89 | KMT2A (0.39) | KMT2AMEN1F10TP53USP2 | |
| SCHEMBL29440704 | 0.89 | KMT2A (0.40) | KMT2AMEN1F10LRRK2SCN2A | |
| SCHEMBL22734599 | 0.89 | KMT2A (0.40) | KMT2AMEN1F10LRRK2SCN2A | |
| SCHEMBL29440726 | 0.89 | KMT2A (0.40) | KMT2AMEN1F10TP53USP2 | |
| SCHEMBL22734589 | 0.89 | KMT2A (0.40) | KMT2AMEN1F10TP53USP2 | |
| SCHEMBL22734543 | 0.88 | KMT2A (0.41) | KMT2AMEN1F10SCN2ASCN10A | |
| SCHEMBL29440697 | 0.88 | KMT2A (0.41) | KMT2AMEN1F10SCN2ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448391-B2 | Bicyclic derivatives for treating endoparasites | ELANCO TIERGESUNDHEIT AG (CH) | 2025-10-21 | — | — | US | claimed |
| US-20240360116-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (SZ) | 2024-10-31 | — | — | US | claimed |
| CN-116888124-A | Bicyclic derivatives | 礼蓝动物保健有限公司 | 2023-10-13 | — | — | CN | claimed |
| US-20220242857-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | ELANCO TIERGESUNDHEIT AG (CH) | 2022-08-04 | — | — | US | claimed |
| CN-114206860-A | Bicyclic derivatives for the treatment of endoparasites | 礼蓝动物保健有限公司 | 2022-03-18 | — | — | CN | claimed |
| US-20200385398-A1 | NEW BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG | 2020-12-10 | — | — | US | claimed |
| WO-2020247747-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | ELANCO TIERGESUNDHEIT AG (CH) | 2020-12-10 | — | — | WO | claimed |
| US-20240360116-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (SZ) | 2024-10-31 | — | — | US | disclosed |
| WO-2024213752-A1 | LONG-TERM PREVENTION AND/OR TREATMENT OF A DISEASE BY SLO-1 INHIBITORS | ELANCO ANIMAL HEALTH GMBH (DE) | 2024-10-17 | — | — | WO | disclosed |
| CN-116888124-A | Bicyclic derivatives | 礼蓝动物保健有限公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2022117783-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2022-06-09 | — | — | WO | disclosed |
| US-20200385398-A1 | NEW BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG | 2020-12-10 | — | — | US | disclosed |
| US-20200385398-A1 | NEW BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG | 2020-12-10 | — | — | US | disclosed |
| WO-2020247747-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | ELANCO TIERGESUNDHEIT AG (CH) | 2020-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448391-B2 | Bicyclic derivatives for treating endoparasites | TBXA2R, PIGS, CYCS | KMT2A 2765/4885MEN1 2037/4885F10 1143/4885 |
| US-20240360116-A1 | BICYCLIC DERIVATIVES | FABP3, CYCS, TNNI3 | KMT2A 2925/4885MEN1 2797/4885F10 756/4885 |
| US-20220242857-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | TBXA2R, PIGS, CYCS | KMT2A 2765/4885MEN1 2037/4885F10 1143/4885 |
| US-20200385398-A1 | NEW BICYCLIC DERIVATIVES | CYCS, FABP3, TNNI3 | KMT2A 3657/4885MEN1 3381/4885F10 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.